Which pharmacological feature best distinguishes proton pump inhibitors (PPIs) from H2 receptor antagonists in the management of peptic ulcer disease?

Explanation

## Mechanism-Based Distinction Between PPIs and H2 Blockers ### Proton Pump Inhibitors (PPIs) **Key Point:** PPIs bind irreversibly to the H+/K+-ATPase pump (the final common pathway of acid secretion) and require new protein synthesis for acid secretion to resume, resulting in a duration of action of 24–48 hours even after drug discontinuation. **High-Yield:** This irreversible mechanism makes PPIs superior to H2 blockers for: - Severe acid-peptic disease - GERD with erosive esophagitis - Zollinger–Ellison syndrome - NSAID-induced ulcers ### H2 Receptor Antagonists **Key Point:** H2 blockers (e.g., ranitidine, famotidine) competitively antagonize histamine at H2 receptors on parietal cells. They are reversible inhibitors with a shorter duration of action (8–12 hours) and require dosing 2–3 times daily. ### Comparative Table | Feature | PPIs | H2 Blockers | | --- | --- | --- | | **Mechanism** | Irreversible H+/K+-ATPase inhibition | Competitive H2 receptor antagonism | | **Site of Action** | Final common pathway (proton pump) | Upstream (histamine receptor) | | **Duration** | 24–48 hours | 8–12 hours | | **Reversibility** | Irreversible | Reversible | | **Acid Suppression** | ~90% | ~70% | | **Dosing Frequency** | Once or twice daily | 2–3 times daily | | **Onset** | 2–3 days (steady state) | 30 minutes to 1 hour | **Clinical Pearl:** The irreversible nature of PPI action is the single most important pharmacological distinction and explains why PPIs are now first-line for most acid-peptic disorders, having largely replaced H2 blockers in clinical practice. **Mnemonic:** **"PPI = Pump Permanently Inhibited"** — remember the irreversible, long-lasting effect that distinguishes PPIs from the reversible H2 blockade.